Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
CBL-514
An investigational localized fat-reduction small-molecule injection, studied for abdominal subcutaneous fat reduction rather than whole-body obesity treatment. Not a peptide.
Apitegromab
An investigational antibody that inhibits myostatin activation, with a peer-reviewed Phase 2 trial showing less DXA-measured lean-mass loss during tirzepatide treatment, but no proven functional outcome in obesity.
How far human research has progressed
CBL-514
Completed controlled Phase 2 and Phase 2b trials for localized abdominal subcutaneous fat reduction; pivotal Phase 3 started September 2026Apitegromab
Completed randomized, double-blind, placebo-controlled Phase 2 (EMBRAZE) in obesity; peer reviewed in Nature Medicine, 8 June 2026Claim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
CBL-514
Controlled Phase 2/2b evidence supports reduction of treated-area abdominal subcutaneous fat measured by imaging and rating scales. This is local fat reduction (body contouring), not evidence of systemic weight loss, obesity treatment, weight-regain prevention or metabolic benefit.
Apitegromab
Controlled Phase 2 evidence supports less DXA-measured lean-mass loss during tirzepatide-associated weight loss over 24 weeks. DXA lean mass is not synonymous with skeletal muscle, and the trial does not establish better strength, mobility, frailty or long-term outcomes.
Human research context
CBL-514
Adults in randomized placebo-controlled abdominal fat-reduction trials published in Aesthetic Surgery Journal; a separate sponsor-reported Phase 2 trial in Dercum's disease.Apitegromab
102 adults with overweight or obesity receiving tirzepatide in EMBRAZE.Human efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
CBL-514
Apitegromab
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
CBL-514
Apitegromab
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
CBL-514
Apitegromab
Regulatory status (legal position, not proof it works)
CBL-514
Check jurisdiction-specific details in the profile.
Not approved for marketing anywhere. Caliway reported first patient dosed in the pivotal global Phase 3 SUPREME-01 trial (approximately 320 participants, US and Canada) on 23 September 2026 for large-area abdominal subcutaneous fat reduction. A trial start is not evidence of efficacy.
Apitegromab
Check jurisdiction-specific details in the profile.
Not approved for any indication in our record. Obesity/body-composition use is investigational.
Common claims
CBL-514
- · Reduces abdominal subcutaneous fat in the injected area
- · Treats obesity or causes weight loss
- · Prevents weight regain after GLP-1 medicines
Apitegromab
- · Reduces lean-mass loss during GLP-1-based weight loss
- · Improves strength or prevents frailty in obesity
How settled our evidence rating is
CBL-514
Apitegromab
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
CBL-514
No human cancer effect is established in our record.Apitegromab
No human cancer effect is established in our record.What this adds up to, in plain English
CBL-514
Real controlled human trials exist, but questions about approval, how long benefits last, or long-term safety are still open.Apitegromab
Real controlled human trials exist, but questions about approval, how long benefits last, or long-term safety are still open.A comparison is not a recommendation